Sopharma AD

zł 14.40As of Sun 8 Nov 2026, 12:00 UTC

WSE:SPHHealthcare

Country Poland

PE (Fwd) 11.98

TSR 10Y CAGR 12.28%

Div yield —

ROE 15.06%

Medical Distribution

Beta (5Y) (0.01)

PE TTM 22.09

TSR TTM 14.47%

Mkt cap zł 7.609B

ROIC 10.88%

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

zł 15

7.32%

(39.41%)

Price above Reference Value

TTM

FYE 31 Dec EUR

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

5Y

10Y

Peers

1.400

Revenue€B

—

—

—

—

—

—

0.843

0.954

1.084

1.329

1.467

16.41%

—

33

—

Revenue growth%

—

—

—

—

—

—

—

13.23

13.66

22.58

10.35

13.66

—

97

24.01

Gross margin%

—

—

—

—

—

—

21.43

21.65

21.33

23.36

24.02

21.54

—

86

6.21

Operating margin%

—

—

—

—

—

—

5.35

5.25

4.07

5.60

6.20

5.30

—

80

5.77

Net margin%

—

—

—

—

—

—

4.28

5.12

3.58

4.95

5.79

4.61

—

86

22.09

P/E ratio (avg)x

—

—

—

—

—

—

7.059

7.958

13.39

16.68

13.08

10.68

—

69

22.57

EV/EBITx

—

—

—

—

—

—

8.406

10.01

16.95

18.45

14.95

13.48

—

29

1.46

FCF yield (avg)%

—

—

—

—

—

—

17.21

0.23

(4.37)

(5.77)

2.29

(2.07)

—

23

1.87

FCF margin%

—

—

—

—

—

—

5.20

0.09

(2.10)

(4.76)

1.73

(1.00)

—

57

0.323

FCF / Net incomex

—

—

—

—

—

—

1.215

0.018

(0.585)

(0.962)

0.299

(0.284)

—

29

10.88

ROIC%

—

—

—

—

—

—

9.36

10.33

7.79

10.62

11.18

9.84

—

77

15.06

Return on equity%

—

—

—

—

—

—

10.09

13.33

9.81

14.64

15.23

11.71

—

97

7.48

Return on assets%

—

—

—

—

—

—

5.67

6.34

4.25

6.22

7.56

5.94

—

86

0.15

EPS€

—

—

—

—

—

—

0.29

0.35

0.24

0.19

0.25

(12.77%)

—

—

—

EPS growth%

—

—

—

—

—

—

—

22.35

(33.23)

(18.75)

29.21

(18.75)

—

96

0.97

Bookvalue per sh€

—

—

—

—

—

—

2.86

2.72

2.53

1.41

1.69

(21.11%)

—

—

0.05

FCF per share€

—

—

—

—

—

—

0.35

0.01

(0.14)

(0.18)

0.07

(98.17%)

—

—

—

Dividend per sh€

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Div yield (avg)%

—

—

—

—

—

—

—

—

—

—

—

—

—

79

—

Payout ratio%

—

—

—

—

—

—

—

—

—

—

—

—

—

32

528.4

Shares (diluted)M

—

—

—

—

—

—

124.8

138.2

164.7

343.2

◌343.2

40.11%

—

100

—

Buyback yield%

—

—

—

—

—

—

—

(10.76)

(19.21)

(108.31)

◌—

(19.21)

—

100

0.534

D/E ratiox

—

—

—

—

—

—

0.377

0.475

0.588

0.648

0.494

0.531

—

43

1.961

Enterprise value€B

—

—

—

—

—

—

0.379

0.502

0.747

1.373

1.361

53.61%

—

50

66.11

LT debt€M

—

—

—

—

—

—

14.06

28.73

32.93

57.27

66.11

59.69%

—

40

Peers (US$1.989B)

Cap (US$)

PE

Liaoning Cheng Da Co.…

2.284B

9.697x

Qingdao Baheal Medical…

2.019B

56.59x

China Meheco Group Co.…

2.002B

43.14x

China National Accord…

1.847B

11.61x

Capital

TTM

5Y

10Y

Leveragex

2.006

2.075

2.075

EBIT/Intx

7.632

7.766

7.766

Own earn%

—

—

—

Sh yield%

—

(19.21)

(19.21)

Owners

Insiders/Inst%

9.85

0.28

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

4/4

Revenue growth years

3/3

EPS growth years

1/3

Dividend streakyrs

1

Op margin range%

4–6

$1 testx

1.5

Incr. ROIC%

11

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

€1.329B

16.41%

1.00×

Cost of revenue

€1.019B

15.45%

0.98×

Operating expenses

€236.1M

20.32%

1.10×

Asset mix

Share

Trend

Other

84.30%

Goodwill & intangibles

12.26%

Cash and investments

3.45%

Reinvestment returns

4Y median

Trend

Reinvestment rate

15.82%

Return on capital

9.84%

Spread over hurdle

2.85%